APE1 Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.90 |
| 52 Week High | CHF 27.80 |
| 52 Week Low | CHF 4.50 |
| Beta | 1.98 |
| 11 Month Change | 25.35% |
| 3 Month Change | 29.93% |
| 1 Year Change | 38.20% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| APE1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 1.0% |
| 1Y | 38.2% | -17.7% | 11.2% |
Return vs Industry: APE1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: APE1 exceeded the German Market which returned 10.7% over the past year.
Price Volatility
| APE1 volatility | |
|---|---|
| APE1 Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APE1's share price has been volatile over the past 3 months.
Volatility Over Time: APE1's weekly volatility has decreased from 29% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| APE1 fundamental statistics | |
|---|---|
| Market cap | €7.73m |
| Earnings (TTM) | -€11.54m |
| Revenue (TTM) | €1.46m |
5.3x
P/S Ratio-0.7x
P/E RatioIs APE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APE1 income statement (TTM) | |
|---|---|
| Revenue | CHF 1.38m |
| Cost of Revenue | CHF 6.93m |
| Gross Profit | -CHF 5.55m |
| Other Expenses | CHF 5.38m |
| Earnings | -CHF 10.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -401.85% |
| Net Profit Margin | -791.44% |
| Debt/Equity Ratio | 0% |
How did APE1 perform over the long term?
See historical performance and comparison